Hillhouse Investment Management, Ltd.

Related company / holding

Insider activity · 24 months0 buys1 saleCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 1 saleJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (0 ops.)

—

▼ Sales (2 ops.)

€20.0M

Latest filing published 03 Feb 2026 for ArriVent Biopharma, Inc., €11.2M. Read the official filing

Filing timeline

BuySale

Hillhouse Investment Management, Ltd.

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

Hillhouse Investment Management, Ltd.: trading record in brief

Hillhouse Investment Management, Ltd. discloses dealings in 2 companies, chiefly ArriVent Biopharma, Inc. and Enfusion, Inc. Over a trading history stretching from 25 October 2021 to 10 December 2025, the count stands at 3 filings.

Every open-market trade on record is a sale: 2 sales worth €20.0M. 2026 to date brings no purchases and 1 sale.

Most recently, on 3 February 2026, the filings show an open-market sale worth €11.2M in ArriVent Biopharma, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.